Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 May 26

PMID 16723564

Citations 102

Authors

E E McKee

M Ferguson

A T Bentley

T A Marks

Affiliations

Soon will be listed here.

Abstract

The effects of a variety of oxazolidinones, with different antibacterial potencies, including linezolid, on mitochondrial protein synthesis were determined in intact mitochondria isolated from rat heart and liver and rabbit heart and bone marrow. The results demonstrate that a general feature of the oxazolidinone class of antibiotics is the inhibition of mammalian mitochondrial protein synthesis. Inhibition was similar in mitochondria from all tissues studied. Further, oxazolidinones that were very potent as antibiotics were uniformly potent in inhibiting mitochondrial protein synthesis. These results were compared to the inhibitory profiles of other antibiotics that function by inhibiting bacterial protein synthesis. Of these, chloramphenicol and tetracycline were significant inhibitors of mammalian mitochondrial protein synthesis while the macrolides, lincosamides, and aminoglycosides were not. Development of future antibiotics from the oxazolidinone class will have to evaluate potential mitochondrial toxicity.

Citing Articles

Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics.

Bibel B, Raskar T, Couvillion M, Lee M, Kleinman J, Takeuchi-Tomita N Nucleic Acids Res. 2025; 53(3).

PMID: 39907106 PMC: 11795202. DOI: 10.1093/nar/gkaf046.

Antibiotic-Induced Immunosuppression-A Focus on Cellular Immunity.

Snow T, Singer M, Arulkumaran N Antibiotics (Basel). 2024; 13(11).

PMID: 39596729 PMC: 11591424. DOI: 10.3390/antibiotics13111034.

A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens.

Molasky N, Zhang Z, Gillespie J, Domagala J, Reyna D, Lipka E Antimicrob Agents Chemother. 2024; 68(12):e0074524.

PMID: 39470194 PMC: 11619354. DOI: 10.1128/aac.00745-24.

Immune modulatory effects of tulathromycin, gamithromycin, and oxytetracycline in cattle.

Wheat W, Chow L, Still-Brooks K, Moore-Foster R, Herman J, Hunter R BMC Vet Res. 2024; 20(1):456.

PMID: 39385141 PMC: 11462805. DOI: 10.1186/s12917-024-04254-x.

Oxazolidinone antibiotics impair megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets.

Milosevic T, Vertenoeil G, Vainchenker W, Tulkens P, Constantinescu S, Van Bambeke F Antimicrob Agents Chemother. 2024; 68(10):e0053324.

PMID: 39297641 PMC: 11460550. DOI: 10.1128/aac.00533-24.

References

Genin M, Allwine D, Anderson D, Barbachyn M, Emmert D, Garmon S . Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J Med Chem. 2000; 43(5):953-70. DOI: 10.1021/jm990373e. View

Yoon E, Jo Y, Choi S, Lee T, Rhee J, Yoo M . In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria. Antimicrob Agents Chemother. 2005; 49(6):2498-500. PMC: 1140508. DOI: 10.1128/AAC.49.6.2498-2500.2005. View

Chopra I, Roberts M . Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65(2):232-60 ; second page, table of contents. PMC: 99026. DOI: 10.1128/MMBR.65.2.232-260.2001. View

Kuter D, Tillotson G . Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001; 21(8):1010-3. DOI: 10.1592/phco.21.11.1010.34517. View

Zhou C, Swaney S, Shinabarger D, Stockman B . 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother. 2002; 46(3):625-9. PMC: 127483. DOI: 10.1128/AAC.46.3.625-629.2002. View

Aoki H, Ke L, Poppe S, Poel T, Weaver E, Gadwood R . Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother. 2002; 46(4):1080-5. PMC: 127084. DOI: 10.1128/AAC.46.4.1080-1085.2002. View

Lovering A, Zhang J, Bannister G, Lankester B, Brown J, Narendra G . Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002; 50(1):73-7. DOI: 10.1093/jac/dkf066. View

Gerson S, Kaplan S, Bruss J, Le V, Arellano F, Hafkin B . Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002; 46(8):2723-6. PMC: 127358. DOI: 10.1128/AAC.46.8.2723-2726.2002. View

Sciotti R, Pliushchev M, Wiedeman P, Balli D, Flamm R, Nilius A . The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. Bioorg Med Chem Lett. 2002; 12(16):2121-3. DOI: 10.1016/s0960-894x(02)00352-9. View

10.

Turton J, Andrews C, Havard A, Robinson S, York M, Williams T . Haemotoxicity of thiamphenicol in the BALB/c mouse and Wistar Hanover rat. Food Chem Toxicol. 2002; 40(12):1849-61. DOI: 10.1016/s0278-6915(02)00178-3. View

11.

Apodaca A, Rakita R . Linezolid-induced lactic acidosis. N Engl J Med. 2003; 348(1):86-7. DOI: 10.1056/NEJM200301023480123. View

12.

YUNIS A . Chloramphenicol toxicity: 25 years of research. Am J Med. 1989; 87(3N):44N-48N. View

13.

Brickner S, Hutchinson D, Barbachyn M, Manninen P, Ulanowicz D, Garmon S . Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996; 39(3):673-9. DOI: 10.1021/jm9509556. View

14.

Barbachyn M, Hutchinson D, Brickner S, Cynamon M, Kilburn J, Klemens S . Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem. 1996; 39(3):680-5. DOI: 10.1021/jm950956y. View

15.

Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, JARREAU F . Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther. 1996; 277(1):253-64. DOI: 10.1163/2211730x96x00144. View

16.

Lin A, Murray R, Vidmar T, Marotti K . The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997; 41(10):2127-31. PMC: 164081. DOI: 10.1128/AAC.41.10.2127. View

17.

SHAPIRO L, Knowles S, Shear N . Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997; 133(10):1224-30. View

18.

Naitoh T, Mishima M, Kawaguchi S, Matsui K, Andoh T, Kagei K . Absorption, distribution, metabolism and excretion of a new, 14C-labelled oxazolidinone MAO-A inhibitor in rat and dog. Xenobiotica. 1997; 27(10):1053-70. DOI: 10.1080/004982597240028. View

19.

Cynamon M, Klemens S, Sharpe C, Chase S . Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1999; 43(5):1189-91. PMC: 89131. DOI: 10.1128/AAC.43.5.1189. View

20.

Riesbeck K, Bredberg A, Forsgren A . Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob Agents Chemother. 1990; 34(1):167-9. PMC: 171543. DOI: 10.1128/AAC.34.1.167. View